AstraZeneca's new myasthenia gravis antibody drug approved in China, to be administered once every 8 weeks

2025-04-22 14:42:51

On April 22, AstraZeneca announced that the marketing application for ravulizumab injection has been approved by the China National Medical Products Administration (NMPA) for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) antibodies. Ravulizumab is a long-acting complement C5 protein inhibitor that is administered once every 8 weeks.

AstraZeneca

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Important events and data forecast for next week - China's foreign exchange reserves, trade account, CPI data, interest rate decisions of the Bank of England and the United States
                            2025-05-04

                                    Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.
                            2025-05-02

                                    Donghua Software: Donghua Fast and Laibin Sugar Bureau jointly promote sugar industry AI big model
                            2025-05-06

                                    US judge rules Apple violated order to reform App Store
                            2025-05-01

                                    Innovative drug concepts continue to adjust BeiGene's stock price fell nearly 9%
                            2025-05-07